Verve Therapeutics Inc Revenue Growth Rates (VERV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Verve Therapeutics Inc   (NASDAQ: VERV)
 

VERV's Revenue Growth by Quarter and Year

Verve Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VERV Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 32.98
FY 32.98





VERV Revenue first quarter 2025 Y/Y Growth Comment
Verve Therapeutics Inc achieved in the first quarter 2025, above Company average Revenue surge of 478.53% year on year, to $ 32.98 millions.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Revenue growth. While Verve Therapeutics Inc ' s Revenue doubling of 478.53% ranks overall at the positon no. 317 in the first quarter 2025.


VERV Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 154.47 % 408.91 % -
3rd Quarter September - 120.19 % 235.48 % -
2nd Quarter June - 220.1 % - -
1st Quarter March 478.53 % 307.14 % - -
FY   - 175.23 % 505.67 % -

Financial Statements
Verve Therapeutics Inc 's first quarter 2025 Revenue $ 32.98 millions VERV's Income Statement
Verve Therapeutics Inc 's first quarter 2024 Revenue $ 5.70 millions Quarterly VERV's Income Statement


VERV Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 90.39 % 64.74 % 8.6 %
3rd Quarter September - 2.69 % 49.28 % -
2nd Quarter June - 17.37 % 49.29 % -
1st Quarter March 152.11 % 10.89 % 38.61 % -
FY (Year on Year)   - 175.23 % 505.67 % -


Back to VERV Growth rate Comparisons >> Back to VERV Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #88
Overall #317

Revenue Y/Y Growth Statistics
High Average Low
279.7 % 236.51 % 174.98 %
(Jun 30 2024)   (Dec 31 2024)
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #88
Overall #317
Revenue Y/Y Growth Statistics
High Average Low
279.7 % 236.51 % 174.98 %
(Jun 30 2024)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Verve Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
152.11 % 48.41 % 2.59 %
(Mar 31 2025)  


VERV's I. Quarter Q/Q Revenue Comment
Verve Therapeutics Inc achieved in the I. Quarter 2025 above company average sequential Revenue doubling of 152.11%, to $ 32.98 millions, from $13.08 millions in the fourth quarter.
VERV is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Verve Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 103.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #41
Overall #103
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #41
Overall #103
Revenue Q/Q Growth Statistics
High Average Low
152.11 % 48.41 % 2.59 %
(Mar 31 2025)  


VERV's I. Quarter Q/Q Revenue Comment
Verve Therapeutics Inc achieved in the I. Quarter 2025 above company average sequential Revenue doubling of 152.11%, to $ 32.98 millions, from $13.08 millions in the fourth quarter.
VERV is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Verve Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 103.


Verve Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 59.61 $ 32.33 $ 24.40 $ 20.65 $ 16.05
Y / Y Revenue Growth (TTM) 271.44 % 174.98 % 219.91 % 279.7 % -
Year on Year Revenue Growth Overall Ranking # 49 # 39 # 30 # 36 # 0
Seqeuential Revenue Change (TTM) 84.38 % 32.53 % 18.15 % 28.66 % 36.49 %
Seq. Revenue Growth (TTM) Overall Ranking # 325 # 123 # 231 # 298 # 0


Cumulative Revenue growth Comment
Verve Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 271.44% year on year, to $ 60 millions if the fiscal year would have ended in Mar 31 2025.
Verve Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 236.51% and higher than 174.98% growth in Dec 31 2024.
But from twelve months ended Dec 31 2024 rise was beneth at 84.38 % from $32.33 millions achieved in the period from Dec 31 2024 to Mar 31 2024.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at236.51%.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 84.38 % increase from $32.33 millions in the period from Dec 31 2024 to Mar 31 2024.

Among companies within the Healthcare sector 17 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 39 to 49.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 18
Overall # 49

Revenue TTM Y/Y Growth Statistics
High Average Low
279.7 %
 236.51 %
174.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 93
S&P 500 # 325
Cumulative Revenue growth Comment
Verve Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 271.44% year on year, to $ 60 millions if the fiscal year would have ended in Mar 31 2025.
Verve Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 236.51% and higher than 174.98% growth in Dec 31 2024.
But from twelve months ended Dec 31 2024 rise was beneth at 84.38 % from $32.33 millions achieved in the period from Dec 31 2024 to Mar 31 2024.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at236.51%.

Among companies within the Healthcare sector 17 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 39 to 49.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 18
Overall # 49

Revenue TTM Y/Y Growth Statistics
High Average Low
279.7 %
236.51 %
174.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 93
S&P 500 # 325




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VERV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Arvinas Inc 646.25%$ 646.245 millions
Novavax inc 610.30%$ 610.303 millions
Delcath Systems Inc 503.35%$ 503.345 millions
Pluri Inc 501.41%$ 501.408 millions
Zevra Therapeutics Inc 495.65%$ 495.650 millions
Verve Therapeutics Inc 479.03%$ 479.034 millions
Regenxbio Inc 469.79%$ 469.786 millions
Ptc Therapeutics inc 459.73%$ 459.731 millions
Ainos Inc 412.36%$ 412.359 millions
One World Products Inc 386.17%$ 386.170 millions
Petvivo Holdings Inc 365.65%$ 365.647 millions
Celldex Therapeutics inc 345.51%$ 345.513 millions
Ensysce Biosciences Inc 331.69%$ 331.690 millions
Editas Medicine Inc 310.40%$ 310.396 millions
Anaptysbio Inc 286.84%$ 286.837 millions
Tscan Therapeutics Inc 283.57%$ 283.569 millions
Inmune Bio Inc 257.14%$ 257.143 millions


About Verve Therapeutics Inc Revenue Growth Rates (VERV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Verve Therapeutics Inc (CIK 1840574).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-25-070911
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Verve Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.